Cromolyn (Gastrocrom, Nalcrom)
What studies of Cromolyn (Gastrocrom, Nalcrom) found
At a glance, by condition
Both together: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.
6 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Cromolyn (Gastrocrom, Nalcrom) might help some people with long COVID and ME/CFS studied together, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Cromolyn (Gastrocrom, Nalcrom) · Both together is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Both together
Symptoms
Autonomic symptoms1 study · 1 (few people) person took Cromolyn (Gastrocrom, Nalcrom) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · over 30 months (few people)
Autonomic symptoms improved.
The evidence is very uncertain about the effect of cromolyn (Gastrocrom, Nalcrom) on autonomic symptoms in ME/CFS or long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- —
- Outcome
- peak heart rate when walking on cromolyn
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study · 1 (few people) person took Cromolyn (Gastrocrom, Nalcrom) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · over 30 months (few people)
Pain improved.
The evidence is very uncertain about the effect of cromolyn (Gastrocrom, Nalcrom) on pain in ME/CFS or long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- —
- Outcome
- remaining symptoms at one year
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 1 (few people) person took Cromolyn (Gastrocrom, Nalcrom) Uncertain –
Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.
Studies with no comparison group1 in the study · over 30 months (few people)
Too little to say about cognition (brain fog).
Too little to say: cognition (brain fog) got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
- One study saw it get worse, without a test against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- —
- Outcome
- fatigue and cognitive dysfunction on stopping fexofenadine and famotidine
- Effect
- worse (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 1 (few people) person took Cromolyn (Gastrocrom, Nalcrom) Uncertain –
Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.
Studies with no comparison group1 in the study · over 30 months (few people)
Too little to say about fatigue.
Too little to say: fatigue got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
- One study saw it get worse, without a test against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- —
- Outcome
- fatigue and cognitive dysfunction on stopping fexofenadine and famotidine
- Effect
- worse (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 1 (few people) person took Cromolyn (Gastrocrom, Nalcrom) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · over 30 months (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of cromolyn (Gastrocrom, Nalcrom) on daily functioning in ME/CFS or long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- —
- Outcome
- energy and overall function on naltrexone
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took Cromolyn (Gastrocrom, Nalcrom) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all).
Studies with no comparison group1 in the study · over 30 months (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of cromolyn (Gastrocrom, Nalcrom) on overall symptoms in ME/CFS or long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- —
- Outcome
- symptom improvement over 30 months
- Effect
- better
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
Side effects studies reported3 kinds
| Side effect | Studies that reported it |
|---|---|
| Worse symptoms or a flare | 2 studies |
| Fatigue | 1 study |
| Nausea or stomach upset | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
1600 mg at the start
- 2Raise
Raised step by step in 1 of 1 studies
- 3Top dose
Most often 2400 mg (1 of 1 studies)
Doses across 1 study
1600 to 2400 mg.
Each study’s dose, as printed
- 1600-2400 mg daily, placing the entire day’s dose in an opaque bottle that is then filled with water, and sipping the solution throughout the day A Continuous Oral Regimen of High-Dose Cromolyn Sodium Is Effective for Some Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients With Mast Cell Activation Syndrome. (2026)
All papers
- A Continuous Oral Regimen of High-Dose Cromolyn Sodium Is Effective for Some Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients With Mast Cell Activation Syndrome.2026 · case report · 5 in the study
Summary
This retrospective case series described five patients from the authors' clinic with ME/CFS and mast cell activation syndrome; Case 5 also met criteria for Long COVID. The series was not a random sample or a consecutive series. Patients were instructed to take oral cromolyn as a continuous regimen, placing the day's dose in water and sipping it, and to increase from an ineffective 800 mg daily dose to 1600-2400 mg daily until optimal effect. Follow-up by case was 30, 42, 12, 24, and 22 months. Outcomes included a 0-to-100 Wellness score and symptom reports. The authors reported that all five patients benefited from a dose higher than usual and customary recommendations. Wellness scores changed from 20/100 to 70/100 (Case 1), 26/100 to 61/100 (Case 2), 30/100 to the 70-80/100 range (Case 3), and 60/100 to 86/100 (Case 4); Case 5 had no baseline or follow-up wellness value. Symptom improvements included energy, orthostatic stress, rashes, hives, flushing, gastrointestinal symptoms, fatigue, brain fog, steps, and activity. Harms included no side effects in Cases 1 and 5, worsening on lower doses of 400-800 mg daily in Case 1, severe bowel cramps and diarrhea after a missed dose in Case 2, and a wellness decline after a cromolyn shortage in Case 5. The authors noted no evidence of toxicity.
- A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID.2023 · case report · 1 in the study
Summary
This case study reports a 19-year-old male who developed impairment consistent with ME/CFS after SARS-CoV-2 infection. The study reports one patient; there was no comparison group, and outcomes were before-versus-after over 30 months. Treatment included physical therapy; stationary biking and running as graded activity; oral sodium chloride and lower limb compression garments; and medications/supplements: fludrocortisone, midodrine, atenolol, pyridostigmine bromide, ivabradine, clonidine, methylphenidate, fexofenadine, famotidine, cromolyn, quercetin, escitalopram, and naltrexone. The paper reports significant improvement in symptoms over 30 months. With cromolyn, peak walking heart rate fell from the 130–140 bpm range to 100–105 bpm. Stopping fexofenadine and famotidine was accompanied on more than one occasion by increased fatigue and cognitive dysfunction; stopping H1 and H2 antihistamines was associated with worsened concentration and short-term memory. Naltrexone was associated with improved energy and overall function, and the patient reported improvements with low doses of clonidine and methylphenidate. For the first 15 months after infection, he continued to have exercise intolerance, with heart rate reaching 130–150 bpm during each of two 15-min walks daily. At one year, remaining symptoms included daily fatigue; lightheadedness and headaches were infrequent. He later resumed running at 10 min four times a week, increased running by two minutes each week, and in October 2022 competed in an 8 K event. Adverse effects were reported with fludrocortisone, midodrine, atenolol, pyridostigmine bromide, and ivabradine. Limitations stated include possible spontaneous improvement and uncertainty about independent effects of interventions.